Releasing the brakes: the role of immune checkpoint inhibitors in laryngeal cancer

Michail Athanasopoulos , Pinelopi Samara , Georgios Agrogiannis , Ioannis Athanasopoulos , Nikolaos Kavantzas , Efthymios Kyrodimos , Nicholas S. Mastronikolis

Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002292

PDF (2714KB)
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) :1002292 DOI: 10.37349/etat.2025.1002292
Review
research-article
Releasing the brakes: the role of immune checkpoint inhibitors in laryngeal cancer
Author information +
History +
PDF (2714KB)

Abstract

Laryngeal cancer, a subtype of head and neck cancer, poses significant challenges due to its profound impact on essential functions such as speech and swallowing and poor survival rates in advanced stages. Traditional treatments-surgery, radiotherapy, and chemotherapy-are often associated with high morbidity and substantial recurrence rates, emphasizing the urgent need for novel therapeutic approaches. Immune checkpoint inhibitors (ICIs) have revolutionized oncology by countering tumor-induced immune evasion, restoring immune surveillance, and activating T-cell responses against cancer. This review examines the role of ICIs in laryngeal cancer management, with a focus on pembrolizumab and nivolumab (anti-PD-1 agents), which are clinically established, as well as investigational therapies such as dostarlimab (anti-PD-1), atezolizumab (anti-PD-L1), and ipilimumab (anti-CTLA-4). Pembrolizumab, in combination with platinum-based chemotherapy and 5-fluorouracil, is approved as a first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), based on evidence from the Keynote-048 trial. This pivotal trial demonstrated significant overall survival (OS) benefits over the cetuximab-based standard regimen. Similarly, nivolumab showed improved OS in the CheckMate-141 trial, supporting its approval as a second-line therapy for patients with platinum-refractory disease. ICIs have shown durable survival benefits and a more manageable toxicity profile compared to traditional chemotherapy. Immune-related adverse events are generally mild and controllable; however, in some cases, they can become severe and even life-threatening. Furthermore, ICIs are being investigated in combination with radiotherapy, as well as in neoadjuvant and adjuvant settings, where preliminary findings suggest these approaches may enhance efficacy, preserve organ function, and overcome resistance to conventional treatments. The integration of ICIs into multimodal treatment strategies holds promise for transforming the therapeutic landscape of advanced laryngeal cancer. This review synthesizes current evidence, highlights ongoing research, and explores strategies to enhance survival and quality of life for patients facing this challenging malignancy.

Keywords

Laryngeal cancer / immune checkpoint inhibitors / nivolumab / pembrolizumab / PD-1/PD-L1 / CTLA-4 / clinical trials / immune-related adverse events

Cite this article

Download citation ▾
Michail Athanasopoulos, Pinelopi Samara, Georgios Agrogiannis, Ioannis Athanasopoulos, Nikolaos Kavantzas, Efthymios Kyrodimos, Nicholas S. Mastronikolis. Releasing the brakes: the role of immune checkpoint inhibitors in laryngeal cancer. Exploration of Targeted Anti-tumor Therapy, 2025, 6 (1) : 1002292 DOI:10.37349/etat.2025.1002292

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Huang J, Chan SC, Ko S, Lok V, Zhang L, Lin X, et al. Updated disease distributions, risk factors, and trends of laryngeal cancer: a global analysis of cancer registries. Int J Surg. 2024; 110: 810-9.

[2]

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73: 17-48.

[3]

Hashibe M, Boffetta P, Zaridze D, Shangina O, Szeszenia-Dabrowska N, Mates D, et al. Contribution of tobacco and alcohol to the high rates of squamous cell carcinoma of the supraglottis and glottis in Central Europe. Am J Epidemiol. 2007; 165: 814-20.

[4]

Yang D, Shi Y, Tang Y, Yin H, Guo Y, Wen S, et al. Effect of HPV Infection on the Occurrence and Development of Laryngeal Cancer: A Review. J Cancer. 2019; 10: 4455-62.

[5]

Ferlito A, Silver CE, Zeitels SM, Rinaldo A. Evolution of laryngeal cancer surgery. Acta Otolaryngol. 2002; 122: 665-72.

[6]

Baird BJ, Sung CK, Beadle BM, Divi V. Treatment of early-stage laryngeal cancer: A comparison of treatment options. Oral Oncol. 2018; 87: 8-16.

[7]

Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022; 20: 44.

[8]

Prasad V, Kaestner V. Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. Semin Oncol. 2017; 44: 132-5.

[9]

Pembrolizumab (KEYTRUDA) [Internet]. US Food and Drug Administration; [cited 2025 Jan 15]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/pembrolizumab-keytruda

[10]

Nivolumab for SCCHN [Internet]. US Food and Drug Administration; [cited 2025 Jan 15]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/nivolumab-scchn

[11]

Poulose JV, Kainickal CT. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials. World J Clin Oncol. 2022; 13: 388-411.

[12]

Gupta I, Hussein O, Sastry KS, Bougarn S, Gopinath N, Chin-Smith E, et al. Deciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications. Adv Cancer Biol Metastasis. 2023; 8: 100107.

[13]

Granier C, Guillebon ED, Blanc C, Roussel H, Badoual C, Colin E, et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open. 2017; 2: e000213.

[14]

Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27: 450-61.

[15]

Ghosh C, Luong G, Sun Y. A snapshot of the PD-1/PD-L1 pathway. J Cancer. 2021; 12: 2735-46.

[16]

Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 2016; 39: 98-106.

[17]

Garden AS. The larynx and hypopharynx. In: Cox JD, Kian Ang K, editors. Radiation Oncology (9th ed.). Mosby; 2010. pp. 282-308.

[18]

Benner A, Sharma P. Anatomy, Head and Neck: Cervical, Respiratory, Larynx, and Cricoarytenoid. Sharma S, editor. Treasure Island (FL): StatPearls Publishing; 2025.

[19]

Rees LEN, Jones PH, Ayoub O, Gunasekaran S, Rajkumar K, Stokes CR, et al. Smoking influences the immunological architecture of the human larynx. Clin Immunol. 2006; 118: 342-7.

[20]

Jetté M. Toward an Understanding of the Pathophysiology of Chronic Laryngitis. Perspect ASHA Spec Interest Groups. 2016; 1: 14-25.

[21]

Thibeault SL, Rees L, Pazmany L, Birchall MA. At the crossroads: mucosal immunology of the larynx. Mucosal Immunol. 2009; 2: 122-8.

[22]

Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. Curr Opin Immunol. 2010; 22: 223-30.

[23]

Karpathiou G, Dumollard JM, Peoc’h M. Laryngeal Tumor Microenvironment. Adv Exp Med Biol. 2020; 1296: 79-101.

[24]

Johns MM, Kolachala V, Berg E, Muller S, Creighton FX, Branski RC. Radiation fibrosis of the vocal fold: from man to mouse. Laryngoscope. 2012; 122: S107-25.

[25]

Mei Z, Huang J, Qiao B, Lam AK. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. Int J Oral Sci. 2020; 12: 16.

[26]

Clinicaltrials.gov [Internet]. Bethesda: National Library of Medicine; [cited 2025 Jan 15]. Available from: https://clinicaltrials.gov/

[27]

Luginbuhl A, Johnson JM, Scott ER, Harshyne L, Flerova EF, Tuluc M, et al. Neoadjuvant nivolumab with or without IDO inhibitor in head and neck squamous cell carcinoma (HNSCC): Final pathologic and clinical outcomes. J Clin Oncol. 2022; 40: 6070.

[28]

Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021; 22: 450-62.

[29]

Ferris RL, Jr GB, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375: 1856-67.

[30]

Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016; 17: 956-65.

[31]

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, et al. ; KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019; 394: 1915-28. Erratum in: Lancet. 2020;395:272. Erratum in: Lancet. 2020;395:564. Erratum in: Lancet. 2021;397:2252.

[32]

Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G Jr, et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: Updated results of the Phase III KEYNOTE-048 study. J Clin Oncol. 2023; 41: 790-802.

[33]

Frankart AJ, Sadraei NH, Huth B, Redmond KP, Barrett WL, Kurtzweil N, et al. A phase I/II trial of concurrent immunotherapy with chemoradiation in locally advanced larynx cancer. Laryngoscope Investig Otolaryngol. 2022; 7: 437-43.

[34]

Bauman JE, Harris J, Uppaluri R, Yao M, Ferris RL, Chen J, et al. NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. Cancers (Basel). 2021; 13: 2882.

[35]

Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, et al. Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: A multicenter, phase II trial. Clin Cancer Res. 2020; 26: 5140-52. Erratum in: Clin Cancer Res. 2021;27:357.

[36]

Hanna GJ, O’Neill A, Shin KY, Wong K, Jo VY, Quinn CT, et al. Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck. Clin Cancer Res. 2022; 28: 468-78.

[37]

Ferris RL, Moskovitz J, Kunning S, Ruffin AT, Reeder C, Ohr J, et al. Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer. Clin Cancer Res. 2022; 28: 1335-44.

[38]

Johnson JM, Vathiotis IA, Harshyne LA, Ali A, Ad VB, Axelrod R, et al. Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck. J Immunother Cancer. 2023; 11: e007141.

[39]

Gavrielatou N, Doumas S, Economopoulou P, Foukas PG, Psyrri A. Biomarkers for immunotherapy response in head and neck cancer. Cancer Treat Rev. 2020; 84: 101977.

[40]

Bill R, Faquin WC, Pai SI. Assessing PD-L1 Expression in Head and Neck Squamous Cell Carcinoma: Trials and Tribulations. Head Neck Pathol. 2023; 17: 969-75.

[41]

Rodrigo JP, Sánchez-Canteli M, Otero-Rosales M, Martínez-Camblor P, Hermida-Prado F, García-Pedrero JM. Tumor mutational burden predictability in head and neck squamous cell carcinoma patients treated with immunotherapy: systematic review and meta-analysis. J Transl Med. 2024; 22: 135.

[42]

Rasmussen JH, Lelkaitis G, Håkansson K, Vogelius IR, Johannesen HH, Fischer BM, et al. Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. Br J Cancer. 2019; 120: 1003-6.

[43]

Goetz JW, Rabinowits G, Kalman N, Villa A. A Review of Immunotherapy for Head and Neck Cancer. J Dent Res. 2024; 103: 1185-96.

[44]

Davis RJ, Waes CV, Allen CT. Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol. 2016; 58: 59-70.

[45]

Cai L, Li Y, Tan J, Xu L, Li Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023; 16: 101. Erratum in: J Hematol Oncol. 2023; 16:105.

[46]

Dougan M. Understanding and Overcoming the Inflammatory Toxicities of Immunotherapy. Cancer Immunol Res. 2020; 8: 1230-5.

[47]

Postow MA, Hellmann MD. Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018; 378: 1165.

[48]

Dang S, Li X, Liu H, Zhang S, Li W. Toxicity profiles of immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis. Cancer Med. 2024; 13: e7119.

[49]

Wang DY, Salem J, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018; 4: 1721-8. Erratum in: JAMA Oncol. 2018; 4:1792.

[50]

Poto R, Troiani T, Criscuolo G, Marone G, Ciardiello F, Tocchetti CG, et al. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. Front Immunol. 2022; 13: 804597.

[51]

Badran YR, Cohen JV, Brastianos PK, Parikh AR, Hong TS, Dougan M. Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events. J Immunother Cancer. 2019; 7: 226.

[52]

Stroud CR, Hegde A, Cherry C, Naqash AR, Sharma N, Addepalli S, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. 2019; 25: 551-7.

[53]

Homer JJ, Fardy MJ. Surgery in head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016; 130: S68-70. Erratum in: J Laryngol Otol. 2016; 130:792.

[54]

Zotta A, Marciano ML, Sabbatino F, Ottaiano A, Cascella M, Pontone M, et al. Neoadjuvant Immunotherapy in Head and Neck Cancers: A Paradigm Shift in Treatment Approach. Biomedicines. 2024; 12: 2337.

[55]

Runnels J, Bloom JR, Hsieh K, Dickstein DR, Shi Y, Jones BM, et al. Combining Radiotherapy and Immunotherapy in Head and Neck Cancer. Biomedicines. 2023; 11: 2097.

[56]

Sindhu SK, Bauman JE. Current Concepts in Chemotherapy for Head and Neck Cancer. Oral Maxillofac Surg Clin North Am. 2019; 31: 145-54.

[57]

Vallianou NG, Evangelopoulos A, Kounatidis D, Panagopoulos F, Geladari E, Karampela I, et al. Immunotherapy in Head and Neck Cancer: Where Do We Stand? Curr Oncol Rep. 2023; 25: 897-912.

PDF (2714KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉